<DOC>
	<DOCNO>NCT00662792</DOCNO>
	<brief_summary>The primary objective trial establish superiority once-daily Tiotropium plus Salmeterol Inhalation Powder daytime lung function response non-inferiority night-time lung function response comparator treatment inhale establish dose regimen administer 6-week period patient chronic obstructive pulmonary disease ( COPD ) . The main secondary objective evaluate safety Tiotropium plus Salmeterol Inhalation Powder versus comparator treatment .</brief_summary>
	<brief_title>Efficacy Safety Comparison Tiotropium Daily + Salmeterol Daily Twice Daily Versus Tiotropium Daily Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . All patient must sign informed consent consistent ICHGCP guideline local legislation prior studyrelated procedure , include medication washout restriction . 2 . All patient must diagnosis COPD must meet following criterion : relatively stable* airway obstruction postbronchodilator FEV1 &lt; 80 % predict normal postbronchodilator FEV1 &lt; 70 % postbronchodilator FVC Visit 1 ( accord GOLD criterion ) . * The randomisation patient respiratory infection COPD exacerbation 6 week prior Screening Visit ( Visit 1 ) baseline period postpone . Patients may randomise 6 week follow recovery infection exacerbation . Predicted normal value calculate accord ECSC . 3 . Male female patient 40 year age old . 4 . Patients must current exsmokers smoke history 10 packyears . 5 . Patients must able perform technically acceptable pulmonary function test 6 . Patients must able inhale medication competent manner . 7 . Patients must able perform necessary recording diary . 1 . Significant disease COPD 2 . Patients clinically significant abnormal baseline haematology , blood chemistry urinalysis , abnormality defines significant disease define exclusion criterion No . 1 . 3 . Patients recent history myocardial infarction . 4 . Patients unstable lifethreatening cardiac arrhythmia require intervention change drug therapy past year . 5 . Hospitalisation cardiac failure past year . 6 . Malignancy within last five year exclude basal cell carcinoma . 7 . Patients history asthma total blood eosinophil count 600/mm3 . 8 . Patients history life threaten pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis . 9 . Known active tuberculosis . 10 . Patients history alcohol drug abuse . 11 . Thoracotomy pulmonary resection . 12 . Rehabilitation program within last six week 13 . Patients regularly use daytime oxygen therapy 14 . Patients take investigational drug within 30 day 15 . Use allow medication 16 . Known hypersensitivity use drug component study medication . 17 . Pregnant nursing woman 18 . Women childbearing potential use highly effective method birth control . Highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner . Female patient consider childbearing potential unless surgically sterilise hysterectomy bilateral tubal ligation , postmenopausal least two year . 19 . Patients currently participate another study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>